CAR-T and engineered T cell therapies

Clinical MedicineUpdated Oct 5, 2026Version v1

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

249 papers

Active filtersClassification:Core

Showing 25-36 of total 249 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

From Delivery to Design: Site-Specific Genome Engineering for Next-Generation CAR T-Cell Therapy.

Aldahshan H; Al-Hubaysh A; Alrabiah DK; Alturki M; Alkharji RR; Lin S; Aldughaim MS; Albugami R

Jan 1, 2026

2026PubMedDirectly related

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer.

Gupta MK; Vadde R; Nagaraju GP

Jan 1, 2026MedComm

2026PubMedDirectly related

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

Ismail M; Al-Gizey N; Alabed Z; Mustafa N; Al-Najjar E; Hamdaneh Y; Eid N; Esmail A

Jan 1, 2026Pharmaceuticals (Basel, Switzerland)

2026PubMedDirectly related

Barriers and Blueprints: Next-Generation Engineering Strategies for CAR-T Cell Therapy in Gastrointestinal Tumors.

Ismail M; Al-Gizey N; Alabed Z; Mustafa N; Al-Najjar E; Hamdaneh Y; Eid N; Esmail A

Jan 1, 2026Pharmaceuticals (Basel, Switzerland)

2026PubMedDirectly related

AI-powered biotherapies: Artificial intelligence and informatics at the intersection of transfusion medicine and biotherapies.

Goel R; Land K; Schoen B; Vassallo R; Cap B

Jan 1, 2026Transfusion

2026PubMedDirectly related

The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.

Schneider MMK; Müller G; Herbst S; Slesaczeck J; Schmädig R; Schmidt F; Illmer T; Leppla L; Valenta S; De Geest S; Teynor A; Wolfien M; Ernst A; Bischof L; Schmitt J; Hänel M; Metzeler KH; Platzbecker U; Vučinić V; Schetelig J; Bornhäuser M; Middeke JM; Egger-Heidrich K

Jan 1, 2026Annals of hematology

2026PubMedDirectly related

The SPIZ study: rationale and protocol of a randomized controlled trial to optimize interdisciplinary care of patients following cellular therapy through a digitally supported, cross-regional and cross-sectoral care model.

Jan 1, 2026Annals of hematology

2026PubMedDirectly related

Multifaceted roles of chemokines in gastric cancer: From tumor microenvironment modulation to therapeutic targeting (Review).

Li Z; Xiao Z

Jan 1, 2026Oncology letters

2026PubMedDirectly related

Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.

Zuber M; Tan CJ; Caballero J; Somanath PR; Godara A; Elshafie S; Zapata LV

Jan 1, 2026Transplantation and cellular therapy

2026PubMedDirectly related

In vivo CAR T-cell therapy: determinants of response and durability.

Abou-El-Enein M

Jan 1, 2026Blood cancer discovery

2026PubMedDirectly related

Different treatment eras for relapsed and refractory primary mediastinal B-cell lymphoma patients: accessibility to CAR T cells is associated with a better prognosis in a pooled analysis of the REPRIME-FIL and the CART-SIE studies.

Guidetti A; Dogliotti I; Chiappella A; Iannitto E; Evangelista A; Dodero A; Di Rocco A; Balzarotti M; Casadei B; Cavallo F; Re A; Farina M; Bramanti S; Chiusolo P; Martino M; Musso M; Zanni M; Grillo G; Ravano E; Krampera M; Hohaus S; Martelli M; Zacchi G; Visco C; Zinzani PL; Consoli U; Corradini P

Jan 1, 2026Haematologica

2026PubMedDirectly related

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy.

Zhang X; Xia F; Qi K; Xia J; Zhou D; Sun Q; Zhang H; Wang X; Sang W; Li D; Yan Z; Chang AH; Cao J; Pan B

Jan 1, 2026Haematologica